Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling
Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit that will provide the foundation for laboratories […]
Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options
SAN DIEGO, JULY 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement […]
Pillar Biosciences and KeyGene Enter into Licensing Agreement
NATICK, Mass. and WAGENINGEN, Netherlands, April 13, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today announced a non-exclusive licensing agreement with Keygene N.V. related to their patent family entitled Combinatorial sequence barcodes for high throughput screeningfor use in Pillar […]
Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation
NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today announced their receipt of the College of American Pathologists (CAP) Accreditation for its CLIA certified reference lab. As one of the most rigorous laboratory certifications, the […]
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Tan JCO PRecis Oncol 2022 epigenetics germline
Beckman Coulter Life Sciences and Pillar Biosciences Sign Application Development Agreement for the Biomek NGeniuS System
INDIANAPOLIS – (October 31, 2022) – More companies around the world continue turning to Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, for their next generation sequencing (NGS) needs with the Biomek NGeniuS System. The company continues building a robust demonstrated application library as it announces an application development agreement with […]
Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference
NATICK, Mass. – August 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products and technologies to localize testing and reduce time to treatment initiation and overall testing costs, today announced that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will […]
Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal™ Dx Colon Cancer Assay
– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass. – August 22, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment initiation and overall […]
Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit
NATICK, Mass. – August 5, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products and technologies to localize testing and reduce time to treatment initiation and overall testing costs, today announced that Randy Pritchard, Chief Executive Officer, will participate in the “Liquid Biopsy in […]
Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx
– PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass. – July 19, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision […]